Cambridge Investment Research Advisors, Inc. Myovant Sciences Ltd. Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	SELL	$7.78 - $14.69 $7,507 - $14,175	-965 Reduced 2.71%	34,590 $429,000
Q1 2022 May 12, 2022	SELL	$11.38 - $16.4 $13,656 - $19,680	-1,200 Reduced 3.26%	35,555 $473,000
Q4 2021 Feb 03, 2022	SELL	$14.31 - $23.87 $32,197 - $53,707	-2,250 Reduced 5.77%	36,755 $572,000
Q2 2021 Aug 10, 2021	BUY	$17.07 - $24.56 $5,974 - $8,596	350 Added 0.91%	39,005 $888,000
Q1 2021 May 07, 2021	BUY	$20.46 - $25.18 $85,215 - $104,874	4,165 Added 12.08%	38,655 $795,000
Q4 2020 Feb 04, 2021	BUY	$13.8 - $27.62 $8,280 - $16,572	600 Added 1.77%	34,490 $952,000
Q3 2020 Oct 29, 2020	SELL	$14.05 - $22.6 $138,743 - $223,175	-9,875 Reduced 22.56%	33,890 $476,000
Q2 2020 Jul 27, 2020	BUY	$7.34 - $20.84 $140,854 - $399,919	19,190 Added 78.09%	43,765 $902,000
Q1 2020 May 08, 2020	SELL	$6.55 - $14.76 $3,635 - $8,191	-555 Reduced 2.21%	24,575 $185,000
Q4 2019 Feb 04, 2020	BUY	$4.2 - $19.21 $60,501 - $276,720	14,405 Added 134.31%	25,130 $390,000
Q3 2019 Nov 06, 2019	BUY	$5.19 - $9.46 $55,662 - $101,458	10,725 New	10,725 $55,000

Others Institutions Holding MYOV

# of Institutions

Shares Held

61.3K

Call Options Held

Put Options Held

View Full List

About Myovant Sciences Ltd.

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

More about MYOV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account